Aims Cardiac L-type Ca 2þ -currents show distinct alterations in chronic heart failure, including increased single-channel activity and blunted adrenergic stimulation, but minor changes of whole-cell currents. Expression of L-type Ca 2þ -channel b 2 -subunits is enhanced in human failing hearts. In order to determine whether prolonged alteration of Ca 2þ -channel gating by b 2 -subunits contributes to heart failure pathogenesis, we generated and characterized transgenic mice with cardiac overexpression of a b 2a -subunit or the pore Ca v 1.2 or both, respectively. Methods and results Four weeks induction of cardiac-specific overexpression of rat b 2a -subunits shifted steady-state activation and inactivation of whole-cell currents towards more negative potentials, leading to increased Ca 2þ -current density at more negative test potentials. Activity of single Ca 2þ -channels was increased in myocytes isolated from b 2a -transgenic mice. Ca 2þ -current stimulation by 8-Br-cAMP and okadaic acid was blunted in b 2a -transgenic myocytes. In vivo investigation revealed hypotension and bradycardia upon Ca v 1.2-transgene expression but not in mice only overexpressing b 2a . Double-transgenics showed cardiac arrhythmia. Interstitial fibrosis was aggravated by the b 2a -transgene compared with Ca v 1.2-transgene expression alone. Overt cardiac hypertrophy was not observed in any model. Conclusion Cardiac overexpression of a Ca 2þ -channel b 2a -subunit alone is sufficient to induce Ca 2þ -channel properties characteristic of chronic human heart failure. b 2a -overexpression by itself did not induce cardiac hypertrophy or contractile dysfunction, but aggravated the development of arrhythmia and fibrosis in Ca v 1.2-transgenic mice.
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Introduction
Calcium entry through L-type channels, multimers of Ca v 1.2-, b-, and a 2 d-subunits, triggers cardiac contraction. There is consensus that whole-cell current as readout of Ca 2þ -channel activity is largely unchanged in heart failure.
1,2 However, our observation of a huge, counterintuitive increase of single-channel activity in ventricular myocytes from human failing heart led to a more cautious interpretation and a more complex view of Ca 2þ -channel remodelling in heart failure, [3] [4] [5] involving perhaps regulatory or structural alterations which escape detection by standard whole-cell analysis.
b 2 -subunits confer the high-activity gating pattern typical for failing human heart, 6 in rodent cardiac cells 7 and recombinant systems, 8, 9 respectively. Recently, we provided proof-of-concept that the single-channel phenotype of human heart failure can be reproduced in mouse heart by short-term overexpression of a b 2a -subunit (tg ind b 2a ). 9 Acute b 2 -subunit overexpression has been shown to cause cell death 7 and apoptosis 10 in isolated myocytes and lifelong overexpression in a transgenic mouse model resulted in hypertrophy, failure, and premature death, albeit under conditions where whole-cell current density-in contrast to human heart failure-was vastly elevated. 11 This finding may just confirm that chronic increases in calcium load through elevated L-type channel expression and function in the sarcolemma can lead to hypertrophy and failure. 12 Conversely, and of more pathophysiological relevance, in vivo knockdown of b 2 -subunits in a rat model of aortic banding reduced Ca 2þ -current density and attenuated cardiac hypertrophy. 13 Although considered to serve as a functional protein kinase A substrate, 14 b 2 -subunit overexpression was recently reported to blunt adrenergic regulation of Ca 2þ -currents in cardiomyocytes, 15 mimicking another feature of human heart failure. 6, 16, 17 In order to further elucidate the putative role of b 2 -subunits in heart failure, 4 we simulated human pathophysiology with respect to Ca 2þ -channel function, using a genetic mouse approach. Cardiac overexpression of b 2a -subunits was induced in vivo for a period of 4 weeks in mice through continuous application of the selective inducing drug tebufenozide via osmotic pumps. Our aim was to elucidate whether the functional and structural Ca 2þ -channel remodelling-as it occurs in human heart failurewill by itself provoke pathophysiological consequences on cardiac morphology, contraction, or rhythm. To compare, contrast, and combine this strategy with a more conventional approach-an overt and long-term increase in Ca 2þ -current-we also examined the effects of stable cardiac overexpression of the Ca v 1.2 pore-subunit (tg Ca v 1.2), a model of calcium-dependent cardiac hypertrophy and failure. 18, 19 We investigated animals at an age of 4-5 months, i.e. at an age where tg Ca v 1.
2 not yet develop significant hypertrophy or increased activity ('heart-failure phenotype') of ventricular L-type Ca 2þ -channels, respectively.
9,19
2. Methods
Mouse models
All procedures complied with respective laws and local regulations (no IRB approval required) and conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The generation of transgenic mice with inducible, cardiac-specific expression of rat b 2a Ca 2þ -channel subunits (tg ind b 2a , Figure 1A ) has been described previously. 9 Transgenic mice with cardiac expression of the human pore-forming Ca 2þ subunit (tg Ca V 1.2) are described elsewhere. 18, 19 All strains were maintained on an FVB/N background with wild-type littermates serving as control. Experiments were performed with mice of both sexes at an age of 4-5 months. Animals (including wild-type mice) were used for experiments 26-28 days after implantation of osmotic minipumps, which contained the inducing drug tebufenozide (kind gift of Dow AgroSciences, Munich, Germany).
Implantation of osmotic pumps
Mice were anaesthetized by intraperitoneal injection of S-ketamin (Ketanest S w , Pfizer; 125 mg/kg) and medetomidine (Domitor w , Pfizer; 250 mg/kg). Osmotic pumps (Alzet w , Model 2004) were prepared as described by the producer's instructions. During operation, pumps were placed subcutaneously at the animals' back with a connected catheter placed intraperitoneally.
Isolation of ventricular myocytes
Single-ventricular myocytes were isolated from murine hearts by enzymatic dissociation using the method described earlier. 9 In brief, hearts were perfused with a collagenase solution (Worthington type I and II, 75 U/L; CellSystems, St Katharinen, Germany) in a Langendorff setup at 378C and subsequently cut into small chunks. Myocytes were harvested by pouring the suspension through cheesecloth. Viability of yielded cells did not differ between the several genotypes.
Electrophysiological investigation of single-ventricular myocytes
All experiments were performed at room temperature. Singlechannel recordings were performed by using the cell-attached configuration of the patch-clamp technique. 9 Cells were placed in disposable Petri-dishes containing 3 mL of a high-potassium solution (mM: 25 KCl, 120 K-glutamate, 2 MgCl 2 , 10 HEPES, 2 EGTA, 10 dextrose, 1 CaCl 2 , 1 Na 2 -ATP; pH 7.3 with KOH). Patch pipettes (borosilicate glass, 6-8 MV) were filled with pipette solution (mM: 70 BaCl 2 , 110 sucrose, and 10 HEPES; pH 7.4 with TEA-OH). Ba 2þ -currents were elicited by voltage steps (150 ms, 1.66 Hz) from 2100 to þ10 mV or þ20 mV, respectively (!180 sweeps per experiment). Data were sampled at 10 kHz and filtered at 2 kHz (3 dB, four-pole Bessel) by using an Axopatch 1D amplifier (Axon Instruments, Foster City, USA). PCLAMP software (CLAMPEX, FETCHAN, and PSTAT 6) was used for data acquisition and analysis (Axon Instruments). When necessary, analysis of single-channel recordings was performed with correction for multiple channels in a patch. 6 Whole-cell recordings were obtained as described. 20 We used an external solution containing (mM): 137 NaCl, 5.4 CsCl, 2 CaCl 2 , 1 MgCl 2 , 10 dextrose, 10 HEPES (pH 7.4 with NaOH). Pipettes (2-4 MV borosilicate glass) were filled with (mM): 120 CsCl, 1 MgCl 2 , 5 HEPES, 10 EGTA, 4 Mg-ATP (pH 7.2 with CsOH). Giga-Ohm seals (2-5 GV) were formed by gentle suction. Before series resistance compensation, membrane capacitance was measured by means of fast depolarizing ramp pulses (from 240 to 235 mV; 5 ms duration) at the beginning of each experiment. Membrane currents were low-pass filtered at 2 kHz. Starting from a holding potential of 280 mV cell membranes were depolarized to 240 mV for 50 ms to inactivate Na þ -and T-type Ca 2þ -channels. To obtain currentvoltage relationship Ca 2þ -currents were then elicited by 150 ms depolarizing pulses at 10 mV steps (range 230 to þ50 mV). Analysis of whole-cell Ca 2þ -current kinetics was performed as described before. 20 In brief, steady-state activation and inactivation curves were fitted using a Boltzmann equation (Microcal Origin w 6.0 software).
Haemodynamic measurements
Electrocardiograms in conscious, unrestrained mice were recorded by telemetry (DSI, Transoma Medical, USA, TA10EA-F20 transmitters) more than 7 days after implantation of transducers as previously described. 21 Thirty seconds recordings were obtained every 10 min at a sampling frequency of 2 kHz. Periods when mice were at rest (activity ¼ 0) were analysed using the ECG module of ADI Chart v5.5.5 (AD Instruments, Castle Hill, Australia). Aortic and leftventricular catheterization was performed using a 1.4F pressurevolume catheter. Data were recorded and analysed with Chart v5.4 as described before. 22 Mice were anaesthetized with isoflurane (2 vol% in O 2 ) and their body temperature was kept at 378C.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qPCR) was performed as described previously. 23 Briefly, ventricles were rapidly removed from decapitated mice, separated from atria, and cut transversally. The ventricle basis was immediately frozen in liquid Transgenic Ca 2+ -channels and heart failurenitrogen. RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). A total of 1 mg RNA was DNase treated and reverse transcribed according to the manufacturer's protocol by means of the QuantiTect Reverse Transcription Kit (Qiagen). qPCR reactions were run in triplicate on an MX3000P detector (Stratagene, Amsterdam, The Netherlands) using Quantitect SYBR Green mastermix (Qiagen). Cycling conditions: 15 min polymerase activation at 958C and 40 cycles at 958C for 15 s, at 588C for 30 s, and at 728C for 30 s. Gene expression was normalized to b-actin values.
Cardiac histology
After haemodynamic evaluation or ECG recording, hearts were fixed with 4% paraformaldehyde in phosphate-buffered saline, embedded in paraffin, cut in 3 mm slices, and stained either with haematoxylin-eosin or Sirius-red as described before. 22 To allow for determination of myocyte cross-sectional area, heart sections were additionally stained with a green fluorescent dye coupled to wheat germ agglutinin (WGA, Alexa Fluor w 488 conjugate, Invitrogen) and nuclei were counterstained with propidium iodide. Leftventricular myocyte cross-sectional areas were analysed by computer-assisted morphometry 22 using a Zeiss AxioCam MRc camera on an Axiovert 200 inverted microscope with Â40 magnification and the AxioVision Rel. 4.5 software. Quantification of fibrosis revealed by Sirius-red staining was performed by measuring the extent of fibrotic area in heart cross-sections.
Data analyses and statistics
Data are presented as means+SEM. To evaluate effects of b 2a overexpression, the following groups were compared using Student's t-tests unless otherwise indicated: tg ind b 2a vs. wild-type, tg Ca V 1.2-Âtg ind b 2a vs. tg Ca V 1.2, and tg Ca V 1.2 vs. wild-type. P-values ,0.05 were considered significant. ) and the cardiac-specific transgene for expression of the human Ca V 1.2 channel subunit (tg Ca V 1.2). Tebufenozide causes transgenic ecdysone receptors (VgBmEcR) to induce expression of the rat b 2a -subunit. aMHC, a-myosin heavy-chain gene promoter; VgBmEcR, chimeric drosophila/bombyx ecdysone receptor; E/GRE, hybrid ecdysone/glucocorticoid response element; DHSP, minimal heat-shock promoter. (B and C) Induced overexpression of b 2 -subunits led to an increase in ventricular L-type Ca 2þ peak current density in hearts with wild-type (B) or tg Ca V 1.2 genetic background (C ), respectively. In addition, we observed a leftward shift of steady-state activation and inactivation (D and E). No significant changes of time-dependent inactivation (data not shown) due to overexpression of b 2 -subunits could be detected. Wild-type: n ¼ 5-9, tg ind b 2a : n ¼ 3-13, tg Ca V 1.2: n ¼ 4-12, tg Ca V 1.2 Â tg ind b 2a : n ¼ 4-6; *P , 0.05.
Results

Transgenic mouse models
We studied three transgenic mouse-lines expressing distinct Ca 2þ -channel subunits specifically in cardiac myocytes in vivo 9 ( Figure 1A) . Cardiac myocyte-specific transcription of a rat Ca 2þ -channel b 2a subunit (tg ind b 2a ) was induced by specific activation of a hybrid drosophila-bombyx ecdysone receptor by tebufenozide. 9, 24 The second mouse-line, tg Ca V 1.2, exhibits a constitutive cardiac overexpression of the human L-type Ca 2þ -channel pore (Ca V 1.2) and represents an established model of cardiac hypertrophy. 18, 19 Mice combining inducible cardiac expression of the rat b 2a -subunit with constitutive cardiac overexpression of the human Ca V 1. For the present study, mice of all four genotypes received the ecdysone receptor agonist tebufenozide. Treatment for 4 weeks resulted in cardiac-specific overexpression of b 2a subunits in tg ind b 2a at the mRNA level (see Supplementary material online, Figure S1A ). In our previous study we had shown that b 2a overexpression also occurred at the protein level after short-term induction. 9 Human Ca V 1.2 mRNA was exclusively detected in tg Ca V 1.2 hearts (see Supplementary material online, Figure S1B ). In order to test whether the transgenes affected expression of the endogenous Ca 2þ -channel subunits, mRNA from wild-type and transgenic hearts was analysed by quantitative RT-PCR using murinespecific primers (see Supplementary material online, Table S1 ). Importantly, expression of the endogenous Ca V 1.2-or b-subunits did not differ between genotypes (see Supplementary material online, Table S2 ).
Whole-cell Ca 21 currents
Cardiac overexpression of the b 2a -subunit for 4 weeks led to an increase of the Ca 2þ -current density at its maximum (wild-type: 210.3 + 0.9 pA/pF, n ¼ 9 vs. tg ind b 2a : 212.7 + 0.7 pA/pF, n ¼ 13; P , 0.05) and at negative test voltages ( Figure 1B) , while current density at potentials positive to 0 mV suggested rather unchanged maximum conductance G max . A more pronounced elevation across the whole voltage range ( Figure 1C Figure 1D , E) towards more negative membrane potentials. Cell capacitance was not different between genotypes (data not shown). Taken together, long-term overexpression of cardiac b 2 -subunits alone changed whole-cell Ca 2þ -currents in a manner resembling findings from human failing myocardium. Figure 2B, D) . In accordance with the leftward shift of whole-cell current activation, effects of b 2a -overexpression on single-channel gating were more pronounced at þ10 mV compared with þ20 mV ( Figure 2B -E vs. Supplementary material online, Figure S2A-D) . In summary, cardiac overexpression of b 2 -subunits caused L-type Ca 2þ -channel properties similar to those obtained with myocytes from human failing ventricle. To examine phosphorylation-dependent channel modulation, we tested the effects of 8-Br-cAMP (1 mM) and the phosphatase inhibitor Okadaic acid (1 mM) on whole-cell currents in ventricular myocytes from wild-type and tg ind b 2a mice (see Supplementary material online, Figure S3 ). Here, basal levels were only slightly higher in tg ind b 2a myocytes (29.5 + 2.9 pA/pF vs. wild-type 27.5 + 1.6 pA/pF.; P . 0.05, n ¼ 5-6). Significant cAMP-dependent stimulation was evident in wild-type myocytes only (wildtype: 158 + 13%, n ¼ 6, P , 0.05; tg ind b 2a : 116 + 9%, n ¼ 5, P ¼ 0.1). Hence, b 2 -subunit expression resembled another important hallmark of human heart failure 6, 16 that also has been shown for Ca v 1.2-transgenic mice. 12 
Haemodynamic function of transgenic mice during anaesthesia
The effects of transgenic expression of b 2a and Ca V 1.2 subunits on haemodynamic function were assessed by leftventricular microtip catheterization during isoflurane anaesthesia ( Figure 3 ). Mice with a single transgene expressing only the hybrid drosophila/bombyx ecdysone receptor (a-MHC VgBmEcR) did not differ in their haemodynamic function or cardiac structure from non-transgenic littermates (data not shown). Expression of the inducible b 2a -subunit did not affect aortic blood pressure when compared with either wild-type or tg Ca V 1.2 animals ( Figure 3A) . Systolic and diastolic aortic pressures were significantly lower in Ca V 1.2-transgenic mice when compared with wild-type mice ( Figure 3A) . No significant differences in left-ventricular contractility (dp/dt max ) were detected between wild-type and transgenic mice ( Figure 3B) . However, LV relaxation (dp/dt min ) was significantly reduced in Ca V 1.2 transgenic mice ( Figure 3C ). Somewhat unexpected, resting heart rate was only 408 + 20 min 21 in tg Ca V 1.2 mice as opposed to 551 + 20 min 21 in wild-type mice (P , 0.01, Figure 3D ). Moreover, during aortic and leftventricular catheterization, irregularities in cardiac rhythm were observed in double-transgenic but not in control or Figure 4C ).
Electrocardiography in awake animals
In order to test whether bradycardia and arrhythmia were also present in awake, freely moving animals, telemetric ECG transducers were implanted and electrocardiograms were recorded for successive days ( Figure 4A, D, E) . All four mouse strains showed expected diurnal heart-rate variations (data not shown) and tg Ca V 1.2 mice exhibited significant bradycardia during night and daytime ( Figure 4E ). Complementing our catheter data, episodes of arrhythmic beats were observed in 6/10 doubletransgenic mice but only in 1/11 tg Ca V 1.2 animals ( Figure 4D 
Cardiac histopathology and cardiac morphological parameters
Transgenic mice overexpressing Ca V 1.2, b 2a or both Ca 2þ -channel subunits did not display any signs of left-ventricular hypertrophy at 4-5 months of age ( Figure 5A-C) . Ventricle-to-body-weight ( Figure 5A ) or ventricle-weightto-tibia-length ratios (data not shown) did not differ between transgenic strains and wild-type mice. Similarly, wheat germ agglutinin (WGA) staining of mid-ventricular transverse sections ( Figure 5B ) to determine single cardiomyocytes' cross-sectional area did not reveal significant differences between groups ( Figure 5C ). Nppa (atrial natriuretic peptide) expression, however, which is a sensitive and early marker for cardiac load and myocyte hypertrophy, was significantly upregulated 5.0-fold and 4.4-fold in ventricles of tg Ca V 1.2 and tg Ca V 1.2 Â tg ind b 2a mice compared with wild-type, respectively ( Figure 5D) . 
Discussion
Activity of single-ventricular L-type Ca 2þ -channels is significantly increased in human heart failure. 6 Subtle alterations of Ca 2þ -current biophysics and pharmacology were also reported at the whole-cell level. 16, 17 These data are consistent with-though not proof of-the idea that Ca 2þ -current in human heart failure is carried by a reduced number of channels, each individually contributing more current at the expense of a reduced regulatory bandwidth. In order to further elucidate the pathophysiological relevance of the Ca 2þ -channel b 2 -subunit overexpression that we recently found in human heart failure, 9 we now used an induction strategy with continuous administration of the inducing agent tebufenozide for 4 weeks, allowing for examination of long-term effects in vivo. It is important to emphasize that the continued induction of only the b 2 -subunit , and LV relaxation (C, dp/dt min ) were significantly decreased by overexpression of Ca V 1.2. No effects of b 2a subunit overexpression were observed in tg ind b 2a mice (compared with wild-type) or double-transgenic animals (compared with tg Ca V 1.2). LV contractility (B) did not differ significantly between strains. Heart rate (D) was significantly lower in tg Ca V 1.2 mice when compared with wild-type mice (n ¼ 4-6 per genotype, *P , 0.05, **P , 0.01, ***P , 0.001).
transgene was totally sufficient to resemble the Ca 2þ -channel phenotype of human heart failure: † little change (even unchanged at positive test potentials) of whole-cell current density, 1,2 † leftward shift of voltage-dependent activation, 16 † marked enhancement of single-channel activity, 6 and † blunting of the Ca 2þ -current response towards phosphorylating conditions. 6, 16 These findings do not resolve the algebraic conundrum why in failing heart single channels-at least those located at the surface sarcolemma-are twice as active as would be predicted from largely unchanged whole-cell currents, with no direct evidence of a reduced expression of The incidence of arrhythmic beats during microtip catheterization was significantly increased in tg Ca V 1.2 Â tg ind b 2a mice (**P , 0.01). No arrhythmic beats were detected in wild-type or tg ind b 2a mice. (D) Overall, arrhythmic episodes during ECG or catheterization were only seen in 1/11 (9.1%) tg Ca V 1.2, but in 6/10 (60%) double-transgenic mice (*P , 0.05; x 2 test). (E) Heart rate as determined by ECG telemetry in awake animals was significantly lowered in tg Ca V 1.2 mice (n ¼ 5-9 per genotype, 3/5 examined tg Ca V 1.2 mice did not receive tebufenozide, *P , 0.05, **P , 0.01; ***P , 0.001).
channel pore protein. 9 Nor do they completely elucidate the mechanistic basis of hyperactivity of single channels (hyperphosphorylation, change in subunit isoform composition, or a combination of both). Our data do, however, prove that the entire spectrum of functional Ca 2þ -channel remodelling as it occurs in human heart failure can be reproduced by continuing overexpression of a b 2 -subunit alone. This serves as the basis to address the important question whether b 2 -subunit overexpression is an adaptive or maladaptive phenomenon, and-consequently-whether interference with structural remodelling would constitute not only a technically feasible 13, 25 but also a therapeutically promising approach.
In vivo overexpression of b 2 -subunits did not affect systolic contractile function, nor did we observe significant changes in tg Ca V 1.2 or double-transgenic hearts. This argues against a major adaptive role of b 2 -subunit overexpression at least in young animals (4-5 months) as studied here, i.e. during a stage where heart failure is not yet developed. Lower blood pressure in tg Ca V 1.2 and doubletransgenic mice may be explained by the significant bradycardia, as left ventricular dp/dt max was not altered in these mice. In this context, it is intriguing to speculate that reduced ventricular relaxation in Ca V 1.2 transgenic mice may be due to diastolic dysfunction associated with ventricular interstitial fibrosis. Based on these haemodynamic results it should be stressed that all the changes reported below are not indirectly mediated by a grossly distorted haemodynamic state.
Cardiac hypertrophy is not induced by b 2 -subunit overexpression as such. This is highlighted by gross and normalized heart weight, myocyte capacitance and morphometric size, and the lack of ANP increase. Hypertrophy is a known consequence of long-term and extensive increase of Ca 2þ -current density, regardless of whether induced by overexpression of Ca V 1.2 18 or b 2 -subunits. 11 Our results indicate that cardiac hypertrophy is not an immediate, direct consequence of Ca 2þ -channel remodelling. It requires a timeframe of more than 4 weeks and/or a substantial increase of whole-cell Ca 2þ -current density, making indirect mechanisms much more likely.
b 2 -Subunit overexpression alone did not induce fibrosis, but Ca 2þ -channel remodelling led to morphological changes even within a 4 week-period in apparently healthy young animals: cardiac fibrosis developing with Ca V 1.2 overexpression 19 aggravates by additional b 2 -subunit overexpression, along with a potentiated increase of the wholecell current density. Thus, our data are consistent with the view that Ca 2þ -current density-and therefore cellular calcium load-rather than a particular subunit as such induces the morphological alterations found in this and other studies. 11, 18 Note that we cannot exclude that the differences we observed regarding the effects of overexpressing a rat b 2a -subunit on an either (murine) wild-type or (human) Ca v 1.2-transgenic background, respectively, is due to combination of channel subunits from different species.
The one functional consequence that we can trace back directly and exclusively to long-term (or subacute) b 2 -subunit overexpression is the induction of resistance of channels towards cAMP-dependent stimulation. This finding deserves a detailed follow-up on its own, because a reduced bandwidth of-e.g. adrenergic-regulation is certainly an important aspect of heart-failure pathophysiology, and the Ca 2þ channel may be a direct player here rather than just an innocent endpoint of a thoroughly altered signalling cascade. 26 The findings of Miriyala et al., 15 together with our previous 9 and present results provide a molecular basis to explain why individual Ca 2þ channels in heart failure are hyperactive and resistant to stimulation by phosphorylation. It will be tempting to find out whether therapeutic reversal of Ca 2þ -channel remodelling can restitute adrenergic responses in heart-failure models.
The most prominent functional consequence of Ca 2þ -channel remodelling was observed with cardiac rhythm: Ca V 1.2 and double-transgenic animals revealed marked bradycardia under both anaesthetized (catheter data) and conscious (telemetry) conditions. Moreover, arrhythmic events were recorded when Ca V 1.2 (1/11 animals), but in particular when both transgenes were overexpressed (6/10 animals). Bradycardia was not associated with altered atrial morphology or atrio-ventricular conduction block and may be a consequence of an altered adrenergic response in vivo. On the other hand, it is tempting to speculate that heartbeat irregularities may have been triggered by the gross alterations of single-channel activity induced by b 2 -subunit overexpression leading to further enhanced Ca 2þ influx via transgenic Ca V 1.2/b 2a channels as a kind of last straw. The lack of pathology in the presence of b 2 -subunit overexpression alone indicates that the b 2 -subunit may be an essential but by itself not sufficient factor for disturbances in cardiac rhythm. It can be speculated that not (only) the amount of Ca 2þ -influx enhancement, but (also) the underlying mechanism (e.g. increased channel activity vs. increased channel activity plus increased channel density) is essential. The respective roles of single-channel behaviour vs. overall calcium load, as well as the cellular mechanism of arrhythmia need further study.
The short 4 week-period of intervention is likewise an important strength and limitation of our present study. Although our previous study has demonstrated that induction of the tg ind b 2a transgene in vivo occurs and takes effect within 48 h, 9 many pathophysiological sequelae may take more time to develop, and therefore longer treatment and observation periods deserve to be studied. On the other hand, the molecular mechanisms of alterations will be hard to identify as soon as complex haemodynamic and morphological changes ensue in an animal model. In this situation, specific molecular interference (e.g. by siRNA) may be a strategy superior to the transgenic approach. Though the bradycardic and the arrhythmic phenotype of our mouse models are of considerable interest our study was limited to exploration by heart catheter and surface ECG. Thus in depth analysis is needed to reveal the kind and relevance of our observations. We believe that the consequences of Ca 2þ -channel remodelling on the complex electrical behaviour of the heart should be studied in other animal models. Lentiviral gene transfer may offer a means to do such studies in hearts much more similar to human regarding rate and rhythm, such as rabbit, pig, or dog.
In conclusion, cardiac b 2 -subunit overexpression in mice causes a Ca 2þ -channel phenotype typical of human heart failure. When present over 4 weeks, this phenotype causes resistance to cAMP-dependent stimulation, but no other direct functional or morphological defects. Cardiac fibrosis and arrhythmia as found in the context of Ca V 1.2 overexpression become potentiated by b 2 -subunit overexpression. Our data suggest that cardiac hypertrophy and contractile failure would require extended timeframes and/or an extent of overexpression of Ca V 1.2 and/or b 2 -subunit that are not pertinent to the human pathophysiology.
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